Q-omics provides the consensus-scored WFDC8 profile across patient tissues and cancer cell-line models. WFDC8 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, WFDC8 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, WFDC8 RNA expression shows 11,164 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight LIHC, and THCA as cancer lineages where WFDC8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WFDC8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WFDC8 survival associations across molecular data types. WFDC8 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WFDC8 RNA expression–survival associations across cancer types. High WFDC8 expression shows unfavorable associations in LIHC, LUSC, KIRC and DLBC, but favorable associations in BLCA and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for WFDC8 RNA expression.
This table summarizes WFDC8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for WFDC8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WFDC8 shows lower tumor expression in THCA, BRCA and KIRC and higher tumor expression in UCEC, ESCA and LUAD. The THCA box plot shows higher WFDC8 RNA expression in normal versus tumor tissue (log2 FC = −0.355, t-test p < 0.001).
This table shows molecular features associated with WFDC8 in patient tissues and cancer cell lines. In patient samples, WFDC8 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, WFDC8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
